Disappearance of immune deposits with EDTA chelation therapy in a case of IgA nephropathy.
In this report, we describe the development of renal function impairment in a 33-year-old patient with mesangial IgA nephropathy and a history of recent gout. Increased body lead burden was identified with a positive EDTA mobilization test. The patient was treated with 1 g of edetate disodium calcium weekly for 2 months until normalization of urinary lead excretion. Improvement of renal function and proteinuria were noted. It was even more interesting to find that both immunofluorescence and electron microscopy studies of the second biopsy specimen revealed the loss of previous mesangial immune deposits. Our case demonstrated that lead may be a nonspecifically damaging factor related to the deterioration of renal function in patients with preexisting renal disease. Moreover, the disappearance of mesangial immune deposits after chelation therapy has not been previously documented. The pathogenetic basis of this observation is unknown, and its causal relationship with lead requires further elucidation.
Lin
J L
JL
Division of Nephrology, Chang Gung Memorial Hospital, Taipei, Taiwan, ROC.
Lim
P S
PS
D000328:Adult; D000936:Antigen-Antibody Complex / Q000032:analysis*; D015913:Chelation Therapy; D003176:Complement C3 / Q000032:analysis; D004492:Edetic Acid / Q000627:therapeutic use*; D005920:Glomerular Mesangium / Q000276:immunology / Q000648:ultrastructure; D005922:Glomerulonephritis, IGA / Q000209:etiology / Q000276:immunology* / Q000473:pathology; D006801:Humans; D007136:Immunoglobulins / Q000032:analysis; D007854:Lead; D008297:Male
D000936:Antigen-Antibody Complex; D003176:Complement C3; D007136:Immunoglobulins; D007854:Lead; D004492:Edetic Acid